Rucaparib

• CAT Number: I002961
• CAS Number: 283173-50-2
• Molecular Formula: C19H18FN3O
• Molecular Weight: 323.4
• Purity: ≥95%
• Target: PARP
• Solubility: DMSO > 80 mg/ml; Water <1 mg/ml
• Storage: Store at -20°C
• IC50: 1.4 nM (Ki) [1]
• InChI: InChI=1S/C19H18FN3O/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)15-8-13(20)9-16(23-18)17(14)15/h2-5,8-9,21,23H,6-7,10H2,1H3,(H,22,24)
• InChIKey: HMABYWSNWIZPAG-UHFFFAOYSA-N
• SMILES: O=C1NCCC2=C(C3=CC=C(CNC)C=C3)NC4=CC(F)=CC1=C24

Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1, also showing binding affinity to eight other PARP domains.IC50 value: 1.4 nM (Ki) [1]Target: PARP1in vitro: Rucaparib is a potent inhibitor of purified full-length human PARP-1 and shows higher inhibition of cellular PARP in LoVo and SW620 cells. Besides, Rucaparib binds detectably to eight other PARP domains, including PARP2, 3, 4, 10, 15, 16, TNKS1 and TNKS2 [1]. The radio-sensitization by Rucaparib is due to downstream inhibition of activation of NF-κB, and is independent of SSB repair inhibition. Rucaparib could target NF-κB activated by DNA damage and overcome toxicity observed with classical NF-κB inhibitors without compromising other vital inflammatory functions [2]. Rucaparib inhibits PARP-1 activity by 97.1% at a concentration of 1 μM in permeabilised D283Med cells [3].in vivo: Rucaparib is not toxic but significantly enhances temozolomide-induced TGD in the DNA repair protein-competent D384Med xenografts. Pharmacokinetics studies also show that Rucaparib is detected in the brain tissue, which indicates that Rucaparib has potential in intra-cranial malignancy therapy [3]. Rucaparib significantly potentiates the cytotoxicity of topotecan and temozolomide in NB-1691, SH-SY-5Y, and SKNBE (2c) cells. Rucaparib enhances the antitumor activity of temozolomide and indicates complete and sustained tumor regression in NB1691 and SHSY5Y xenografts [4].

Reference

1:Drug Monographs: Olaratumab and Rucaparib. Solimando DA Jr, Waddell JA.Hosp Pharm. 2017 Apr;52(4):258-263. doi: 10.1310/hpj5203-258. PMID: 28515503 2:Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas. Laroche A, Chaire V, Le Loarer F, Algéo MP, Rey C, Tran K, Lucchesi C, Italiano A.J Hematol Oncol. 2017 Apr 11;10(1):84. doi: 10.1186/s13045-017-0451-x. PMID: 28399901 Free PMC Article3:A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors. Kristeleit R, Shapiro GI, Burris HA, Oza AM, LoRusso P, Patel MR, Domchek SM, Balmaña J, Drew Y, Chen LM, Safra T, Montes A, Giordano H, Maloney L, Goble S, Isaacson J, Xiao J, Borrow J, Rolfe L, Shapira-Frommer R.Clin Cancer Res. 2017 Mar 6. doi: 10.1158/1078-0432.CCR-16-2796. [Epub ahead of print] PMID: 28264872 4:Rucaparib: First Global Approval. Syed YY.Drugs. 2017 Apr;77(5):585-592. doi: 10.1007/s40265-017-0716-2. Review. PMID: 28247266 5:A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. Wilson RH, Evans TJ, Middleton MR, Molife LR, Spicer J, Dieras V, Roxburgh P, Giordano H, Jaw-Tsai S, Goble S, Plummer R.Br J Cancer. 2017 Mar 28;116(7):884-892. doi: 10.1038/bjc.2017.36. Epub 2017 Feb 21. PMID: 28222073 Free PMC Article6:Rucaparib Approved for Ovarian Cancer. [No authors listed]Cancer Discov. 2017 Feb;7(2):120-121. doi: 10.1158/2159-8290.CD-NB2016-164. Epub 2017 Jan 5. PMID: 28057616 7:Genomic LOH May Predict Rucaparib Response in Ovarian Cancer. [No authors listed]Cancer Discov. 2017 Jan;7(1):OF8. doi: 10.1158/2159-8290.CD-RW2016-230. Epub 2016 Dec 9. PMID: 27940438 8:Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, Konecny GE, Coleman RL, Tinker AV, O/’Malley DM, Kristeleit RS, Ma L, Bell-McGuinn KM, Brenton JD, Cragun JM, Oaknin A, Ray-Coquard I, Harrell MI, Mann E, Kaufmann SH, Floquet A, Leary A, Harding TC, Goble S, Maloney L, Isaacson J, Allen AR, Rolfe L, Yelensky R, Raponi M, McNeish IA.Lancet Oncol. 2017 Jan;18(1):75-87. doi: 10.1016/S1470-2045(16)30559-9. Epub 2016 Nov 29. PMID: 27908594 Free Article9:Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib. McCormick A, Donoghue P, Dixon M, O/’Sullivan R, O/’Donnell RL, Murray J, Kaufmann A, Curtin NJ, Edmondson RJ.Clin Cancer Res. 2017 Apr 15;23(8):2050-2060. doi: 10.1158/1078-0432.CCR-16-0564. Epub 2016 Oct 4. PMID: 27702817 10:An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma. Nile DL, Rae C, Hyndman IJ, Gaze MN, Mairs RJ.BMC Cancer. 2016 Aug 11;16:621. doi: 10.1186/s12885-016-2656-8. PMID: 27515310 Free PMC Article